Ueda S, Nunn BM, Chauhan R, et al. - Because posterior ocular trauma and the resulting fibrotic retinal complication called proliferative vitreoretinopathy (PVR) are leading causes of blindness in children and young adults, researchers used a previously established swine ocular trauma model that mimics both contusion and penetrating injuries to investigate the impact of dasatinib, a tyrosine kinase inhibitor clinically used to treat chronic myeloid leukemia, on fibrotic changes occurring within the first month following ocular trauma. Dasatinib was given on days 4 and 18 post-trauma through intravitreal injection of either bolus solution or suspension of a sustained release system incorporated in biodegradable poly (lactic-co-glycolic acid) (PLGA) nanoparticles. Injection of dasatinib-incorporated PLGA greatly reduced early retinal fibrotic changes, contributing ultimately to PVR following posterior ocular trauma. Therefore, the sustained dasatinib release system may potentially be used to prevent and/or broaden the surgical treatment window for PVR.